Intertumoral metabolic heterogeneity affects the responses to PD-1 inhibitor therapy, and the balance between distinct metabolic pathways may influence PDAC outcomes and image metabolic heterogeneity in cancer [6]. Here, PDCD1 is linked to cancer.